Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22733780 | 0.93 | CA2 (0.32) | CA2 | |
| SCHEMBL3500822 | 0.86 | CA2 (0.35) | CA2 | |
| SCHEMBL27357836 | 0.78 | — | — | |
| SCHEMBL147056 | 0.78 | — | — | |
| SCHEMBL8007543 | 0.75 | — | — | |
| SCHEMBL31253439 | 0.75 | — | — | |
| SCHEMBL26250416 | 0.73 | ALDH1A1 (0.33) | — | |
| SCHEMBL52 | 0.72 | CA2 (0.35) | CA2 | |
| SCHEMBL27623481 | 0.72 | CA2 (0.35) | CA2 | |
| SCHEMBL3405743 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | ENEVATE CORPORATION (US) | 2023-08-29 | — | — | US | claimed |
| US-10957898-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2021-03-23 | — | — | US | claimed |
| US-20200388880-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS | ENEVATE CORPORATION | 2020-12-10 | — | — | US | claimed |
| US-20200203711-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2020-06-25 | — | — | US | claimed |
| WO-2020132057-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION (US) | 2020-06-25 | — | — | WO | claimed |
| US-11837711-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-12-05 | — | — | US | disclosed |
| US-11837711-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-12-05 | — | — | US | disclosed |
| US-11837711-B2 | Silicon-based energy storage devices with anhydride containing electrolyte additives | ENEVATE CORPORATION (US) | 2023-12-05 | — | — | US | disclosed |
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | ENEVATE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | ENEVATE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | ENEVATE CORPORATION (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210167361-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ANHYDRIDE CONTAINING ELECTROLYTE ADDITIVES | ENEVATE CORPORATION | 2021-06-03 | — | — | US | disclosed |
| US-8476459-B2 | Process for the preparation of 4-sulfinyl-pyrazole derivatives | BASF SE (DE) | 2013-07-02 | — | — | US | disclosed |
| EP-2493860-A1 | PROCESS FOR THE PREPARATION OF 4-SULFINYL-PYRAZOLE DERIVATIVES | BASF SE (DE) | 2012-09-05 | — | — | EP | disclosed |
| US-20120215008-A1 | Process for the Preparation of 4-Sulfinyl-Pyrazole Derivatives | BASF SE (DE) | 2012-08-23 | — | — | US | disclosed |
| WO-2011051284-A1 | PROCESS FOR THE PREPARATION OF 4-SULFINYL-PYRAZOLE DERIVATIVES | BASF SE (DE) | 2011-05-05 | — | — | WO | disclosed |
| US-5039671-A | Bone disorders; calcium or phosphorus inbalance | HOFFMANN-LA ROCHE INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-4906785-A | Novel trifluorinated vitamin D3 intermediates | HOFFMANN-LA ROCHE INC. (US) | 1990-03-06 | — | — | US | disclosed |
| EP-0186102-B1 | CHOLECALCIFEROL DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1989-05-10 | — | — | EP | disclosed |
| EP-0186102-A2 | Cholecalciferol derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200388880-A1 | SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS | SOST, CA1, DUOX2 | CA2 11/4885 |
| US-11742519-B2 | Silicon-based energy storage devices with electrolyte additive compounds | SOST, CA1, DUOX2 | CA2 11/4885 |
| US-20120215008-A1 | Process for the Preparation of 4-Sulfinyl-Pyrazole Derivatives | HCN4, CBR3, SCO2 | CA2 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.